Q1 2026 Recap: Revenue +23%, EPS +38%, 1st FY26 Raise, Cyber Incident Contained — Maintaining Outperform with HIGH Conviction
Key Takeaways
- Massive Q1 beat: Revenue $2.77B (+23% YoY, +22% CC) crushed Street $2.55B by $220M — best revenue beat in 8+ quarters. Non-GAAP EPS $2.50 (+38% YoY) beat Street $2.10 by $0.40. Non-GAAP operating margin 39% sustained. da Vinci procedures +16%; total procedures +17%; Ion +39%; SP +68%. US +14%, OUS +19%. Non-GAAP GM 67.8% +140bp YoY — the YoY GM improvement reverses the FY25 pattern of YoY compression.
- FY26 guide RAISED — first raise of 2026: da Vinci procedure growth 13.5-15.5% (from 13-15%); non-GAAP GM 67.5-68.5% (from 67-68%); tariff impact 100bp (from 120bp). The 13-15% Q4 guide that prompted concern is structurally tracking above with Q1 +16% — classic ISRG conservative-guide-then-raise pattern reasserts.
- Strategic milestones: dV5 installed base ~1,500 systems (13K+ surgeons since launch); 232 dV5 placements Q1 (40 OUS); OUS da Vinci 38% of total procedures (vs 25% a decade ago); Italy/Spain/Portugal direct conversion closed (added 230 employees); SP first non-IDE nipple-sparing mastectomy cases performed; SP stapler moved to broad US launch; force feedback instrument clearances expanded (5 of 6 instruments now cleared for 15 uses). Japan policy improvements effective June 2026 (>200 case hospital reimbursement + 7 new procedure reimbursements).
- Cyber incident contained — unauthorized access to some customer/employee data discovered during Q1; no business or manufacturing disruption; no product impact; insignificant financial impact on Q1; customers + regulators notified. Management strengthening cybersecurity protocols. CMO transition: Dr. Myriam Curet retiring after 20+ years; Dr. Jamie Wong (practicing dV urologist + 10+ years at Intuitive) promoted to CMO.
- Rating: Maintaining Outperform with HIGH conviction. Stock +7.2% to ~$520. The Q1 print is the cleanest validation of the multi-quarter compounder thesis — revenue acceleration, EPS +38%, 1st FY26 raise, multi-platform TAM expansion, conservative-guide pattern reasserted. PT range updated Base $680 / Bull $760 / Bear $530.
Results vs. Consensus
Q1 2026 is the best beat-and-raise print in 8+ quarters. The +23% revenue growth on tough comp combined with +38% EPS growth + 1st FY26 raise resolves the 2026 deceleration concern decisively. ISRG's conservative-guide pattern reasserts itself — initial 2026 guide of 13-15% procedure growth lands Q1 at +16%, supporting the bull thesis that FY26 actual will land 15-16%+.
| Metric | Q1 Actual | Consensus | Beat/Miss | Magnitude |
|---|---|---|---|---|
| Revenue | $2.77B (+23%) | $2.55B | Beat | +$220M / +8.6% |
| da Vinci Procedures | +16% | ~+14% | Beat | +200bp |
| System Placements | 431 (+17%) | ~390 | Beat | +41 |
| Non-GAAP Gross Margin | 67.8% | ~67.0% | Beat | +80bp |
| Non-GAAP Op Margin | 39% | ~37% | Beat | +200bp |
| Non-GAAP EPS | $2.50 (+38%) | $2.10 | Beat | +$0.40 |
| GAAP EPS | $2.28 | $1.95 | Beat | +$0.33 |
YoY View
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | $2.77B | $2.25B | +23% |
| da Vinci Procedures | 847K (+16%) | ~731K | +16% |
| Ion Procedures | 43K (+39%) | ~31K | +39% |
| System Placements | 431 | 367 | +17% |
| dV5 Placements | 232 | ~140 | +66% |
| Non-GAAP EPS | $2.50 | $1.81 | +38% |
| Non-GAAP Gross Margin | 67.8% | 66.4% | +140bp |
QoQ View
| Metric | Q1 2026 | Q4 2025 | QoQ |
|---|---|---|---|
| Revenue | $2.77B | $2.87B | -3.5% |
| System Placements | 431 | 532 | -19% (seasonal) |
| Non-GAAP GM | 67.8% | 67.8% | Flat |
| EPS | $2.50 | $2.53 | Flat |
Revenue Assessment
Revenue +23% YoY with procedure growth +17% — operational momentum acceleration. Composition: US +15% (US da Vinci +14%; cholecystectomy + appendectomy +31%; non-hyst benign gyn +19%); OUS +20% (da Vinci +19%; ION quadrupling). The OUS contribution at 38% of total da Vinci procedures (vs 25% a decade ago) demonstrates the multi-year diversification. Japan + China headwinds persist but absorbed by India + Korea + UK + Taiwan + distributor markets strength. The 30% slow-down vs Q4 (-3.5% QoQ) is normal Q1 seasonality.
Margin Assessment
Non-GAAP GM 67.8% expanded +140bp YoY — first YoY GM expansion in 6 quarters. Drivers: product cost reductions + fixed overhead leverage + tariff impact reduction. dV5 contribution margins now comparable to Xi; Ion contribution margins close to corporate average. Operating margin 39% sustained at industry-leading level despite ongoing investments (Italy/Spain/Portugal direct + Bulgaria facility + new product launches).
EPS Assessment
Non-GAAP EPS $2.50 (+38% YoY) — best YoY growth in many quarters. The +38% is +1500bp above revenue growth — exceptional operating leverage. Composition vs Q1 2025: operating beat ~$0.55 (margin expansion + revenue growth); below-the-line ~$0.10; share count modest reduction. Pro forma tax rate 22% in line with new guidance. The $2.50 trajectory implies FY26 EPS could land $10.40+ vs original implied $10.10 — meaningful upward revision.
Segment Performance
da Vinci — 847K Procedures (+16%); 432K dV5 Installed Base
da Vinci procedures +16% YoY with US +14% (general surgery strength; cholecystectomy + appendectomy +31%; non-hyst benign gyn +19%) and OUS +19% (India + Korea + UK + Taiwan strongest). 431 da Vinci placements (+17% from 367): 232 dV5, 34 SP, 34 XiR, 34 refurbished Xi (priced lower for cost-sensitive segments). dV5 installed base ~1,500 systems with 13,000+ surgeons trained since launch. Trade-ins 119 (+78% vs 67 YoY). US utilization +4%; dV5 utilization ~11% higher than Xi.
Assessment: da Vinci is the structural engine. Multi-platform portfolio (dV5 + Xi + XiR + SP) addressing different price points + use cases. dV5 utilization premium over Xi is the durable margin expansion driver.
Ion — 43K Procedures (+39%); 52 Placements
Ion procedures 43K (+39% YoY). System placements 52 (vs 49 YoY). I&A revenue per procedure ~$2,200 stable.
Assessment: Sustained scaling. Mayo Clinic 2,000-patient study published demonstrating diagnostic yield + early-stage diagnosis improvement.
SP — +68% Procedures; Stapler Broad Launch
SP procedures +68% YoY. First non-IDE nipple-sparing mastectomy cases performed in US. SP stapler moved to broad US launch.
Assessment: SP US TAM expansion accelerating. NSM + multiple GI clearances + stapler broad launch combine to drive 2026-2027 inflection.
Key Topics & Management Commentary
Overall Management Tone: Confident on operational momentum + strategic positioning. The Q1 beat-and-raise reasserts the conservative-guide pattern Investors had questioned in Q4. CMO transition handled smoothly; cyber incident contained.
1. 1st FY26 Guide Raise — Pattern Reasserts
FY26 guide raised: procedure 13.5-15.5% (from 13-15%); GM 67.5-68.5% (from 67-68%); tariff 100bp (from 120bp). 1st raise of FY26.
"We are increasing our forecast and now expect full year da Vinci procedure growth within a range of 13.5% to 15.5%." — Daniel Connally, Head of IR
Assessment: Conservative-guide pattern reasserts. FY26 actual likely lands 15-16%+ if pattern holds.
2. Cyber Incident Contained
Cyber incident discovered Q1 — unauthorized access to some customer + employee data + corporate data in IT business applications. No business/manufacturing disruption; no product impact; insignificant Q1 financial impact.
"The incident did not disrupt our business or manufacturing operations and did not affect our products. It also did not have a significant impact on our first quarter financial results. We have contained the incident, notified customers and informed appropriate data privacy regulators." — Jamie Samath, CFO
Assessment: Contained event. Management transparency + quick containment = appropriate response.
3. CMO Transition — Wong Promoted
Dr. Myriam Curet retiring after 20+ years as CMO; Dr. Jamie Wong promoted to CMO. Wong is a practicing da Vinci urologist with 10+ years at Intuitive.
Assessment: Internal promotion provides continuity. Wong's surgical practice + Intuitive tenure = strong CMO fit.
4. OUS 38% of Total da Vinci Procedures (vs 25% Decade Ago)
Multi-decade OUS diversification — 38% of total da Vinci procedures now OUS (vs 25% decade ago). India + Korea + UK + Taiwan strongest in Q1.
Assessment: Structural OUS expansion. Provides geographic resilience as US growth moderates.
5. Force Feedback Expanded Clearances
FDA clearance for additional uses of Force Feedback instruments — 5 of 6 cleared for 15 uses; Mega SutureCut Needle Driver cleared for 10 uses. Supports broader availability Q2 onward.
Assessment: Force feedback adoption accelerating through 2026. Clinical evidence base building.
6. SP First Non-IDE Nipple-Sparing Mastectomy Cases
First non-IDE NSM cases performed US in Q1. Measured rollout focused on training + support.
Assessment: SP TAM expansion in NSM is meaningful. Measured rollout 2026; revenue contribution 2027.
7. SP Stapler Broad US Launch
SP stapler moved to broad US launch. Will support deeper SP penetration in thoracic + colorectal procedures.
Assessment: SP stapler is unlock for colorectal + thoracic. Multi-quarter ramp.
8. Japan Policy Improvements (Effective June 2026)
Japan MHLW introduced (a) incremental reimbursement for hospitals >200 cases/year + (b) 7 new procedure reimbursements + (c) rectal resection premium reimbursement when performed robotically. All effective June 2026.
Assessment: Japan policy support is the H2 2026 inflection catalyst. Multi-year tailwind.
9. dV5 Installed Base 1,500 Systems / 13K Surgeons
dV5 installed base reaches ~1,500 systems with 13,000+ surgeons trained since launch. ~14% of total da Vinci installed base now dV5.
Assessment: dV5 transition in mid-flight. Multi-year runway as Xi base converts to dV5.
10. Italy/Spain/Portugal Direct Conversion Closed
Distributor acquisition closed Q1. 230 employees added. Going-direct strategy expansion completed.
Assessment: Initial OpEx drag Q1-Q2; margin benefit emerges 2026 H2 onward.
Guidance & Outlook
| Metric | FY26 Updated (Q1) | FY26 Initial (Q4) | Change |
|---|---|---|---|
| da Vinci Procedure Growth | 13.5-15.5% | 13-15% | Raised low end |
| Non-GAAP Gross Margin | 67.5-68.5% | 67-68% | Raised 50bp |
| Tariff Impact | 100bp | 120bp | Reduced |
| Non-GAAP OpEx Growth | 11-14% | 11-15% | Tightened |
| Non-GAAP Tax Rate | 22-23% | 22-23% | Reaffirmed |
| Other Income | $315-335M | $355-375M | Lowered (lower cash bal) |
Analyst Q&A Highlights
FY26 Procedure Guide Conservatism
Q: "Q1 +16% vs initial 13-15% guide. Even after the raise to 13.5-15.5%, doesn't Q1 already imply 16%+? Why not a larger raise?"
— Larry Biegelsen, Wells Fargo
A: "We are increasing our forecast and now expect full year da Vinci procedure growth within a range of 13.5% to 15.5%. We continue to expect primary growth drivers in 2026 to be generally consistent with those in 2025... Our updated range continues to consider the potential impact of changes to ACA premium subsidies and patient behavior in the U.S., capital pressure in parts of Europe..."
— Daniel Connally, Head of IR
Assessment: Conservative-guide pattern intact. Math implies actual FY26 lands 15-16%+ if Q1 momentum sustains.
Gross Margin YoY Expansion First Time in 6 Quarters
Q: "GM +140bp YoY is the first YoY expansion in 6 quarters. What's driving the inflection?"
— Robbie Marcus, JPMorgan
A: "The year-over-year increase reflects product cost reductions and fixed overhead leverage, partly offset by the impact of tariffs... During the quarter, our da Vinci 5 system achieved contribution margins comparable with our Xi system, and our Ion platform achieved contribution margins that are close to the corporate average."
— Jamie Samath, CFO
Assessment: Platform-margin convergence is the structural shift. dV5 + Ion no longer dilutive at margin level.
Cyber Incident Impact
Q: "The cyber incident — any operational ramifications or regulatory exposure investors should consider?"
— David Roman, Goldman Sachs
A: "The incident did not disrupt our business or manufacturing operations and did not affect our products. It also did not have a significant impact on our first quarter financial results. We have contained the incident, notified customers and informed appropriate data privacy regulators. We are also taking additional steps to further strengthen our cybersecurity protocols."
— Jamie Samath, CFO
Assessment: Contained event. No multi-quarter financial implication signaled.
SP Stapler Broad Launch + NSM
Q: "SP stapler broad launch + first NSM cases — when does SP contribution become material?"
— Anthony Petrone, Mizuho
A: "Recently, U.S. surgeons performed the first non-IDE nipple sparing mastectomy cases as we advance our measured rollout focused on training and support of our customers. We also moved our single-port stapler into broad launch, which will support deeper penetration in thoracic and colorectal procedures."
— David Rosa, CEO
Assessment: SP US TAM ramp in 2026. Material contribution 2027.
Japan Policy Support Quantification
Q: "Japan policy support — 200-case hospital reimbursement + 7 new procedures. How material is this to Japan procedure growth?"
— Travis Steed, BofA
A: "In Q1, the Japanese Ministry of Health, Labor and Welfare recently introduced incremental reimbursement for hospitals that exceed robotic procedure volumes of 200 qualifying cases per year. In addition, 7 new procedures have been granted robotic reimbursements starting in June of 2026... While we are encouraged by these steps, we remain cautious in our outlook for the Japanese market in the short term."
— Jamie Samath, CFO
Assessment: Japan supportive but financial impact lagged due to hospital position recovery. H2 2026 + 2027 visibility.
What They're NOT Saying
- Specific FY26 EPS guidance (not provided)
- Cardiac dV5 procedure ramp specifics
- ASC procedure volume contribution
- Cyber incident remediation cost estimate
- SP NSM revenue contribution timing
- ACA subsidy expiration impact quantification (currently "watching")
Market Reaction
- Pre-print: Stock ~$485; YTD CY26 -12%; trailing 12M -7%; ~48x FY26 EPS
- After-hours: +7-8% on massive beat + 1st raise
- April 22 close: ~$520, +7.2% (+$35); volume 2.5x average
Reaction validates the operational momentum. Sell-side PT raises 10-15% to $560-650 range.
Street Perspective
Debate: Is Conservative-Guide Pattern Reasserting?
Bull view: Yes — Q1 +16% vs 13-15% initial guide is classic ISRG pattern. FY26 actual lands 15-16%.
Bear view: Tougher comps + macro headwinds will compress H2 growth.
Our take: Bull clearly correct. Q1 alone supports FY26 raise to 15%+.
Debate: GM Inflection Sustainability
Bull view: Platform-margin convergence (dV5 ≈ Xi; Ion close to corporate) is structural. FY26 GM 68%+ achievable.
Bear view: Tariff headwinds + facility depreciation persist.
Our take: Bull view supported by Q1 data. GM expansion runway continues.
Debate: ISRG Valuation Recovery
Bull view: Multi-year compounder + multiple TAM unlocks + accelerating operating leverage support 55-60x premium.
Bear view: Medical device sector still pressured; ISRG vulnerable to multiple compression.
Our take: Bull clearly correct. 48x at print is discount; re-rating toward 55x = $620+ achievable.
Model Update Needed
| Item | Prior | New |
|---|---|---|
| FY26 Revenue | $11.6B | $11.9-12.0B |
| FY26 EPS | $10.25 | $10.80 |
| FY26 Procedure Growth | 13-15% | 15-16% (above raised guide) |
| FY27 Revenue | $13.5B | $13.8-14.0B |
| FY27 EPS | $12.70 | $13.20 |
Valuation: PT range updated to Base $680 / Bull $760 / Bear $530. Base 55x FY26 EPS $10.80 + multi-year compounder + accelerating GM. At $520 post-print: base +31%; bull +46%; bear +2%. Up/down ~5:1.
Thesis Scorecard
| Thesis Point | Status |
|---|---|
| Bull #1: Durable procedure growth | Strongly Confirmed (Q1 +16%) |
| Bull #2: dV5 platform mix-up | Confirmed |
| Bull #3: OUS expansion | Confirmed (38% of total da Vinci) |
| Bull #4: Multi-platform TAM expansion | Confirmed (SP NSM + stapler + cardiac) |
| Bull #5: Platform-margin convergence | Newly Confirmed (GM +140bp YoY) |
| Bull #6: Conservative-guide pattern | Reasserted (1st raise) |
| Bear #1: GM compression | Mitigated/Reversed |
| Bear #2: OUS macro headwinds | Mitigating (Japan policy + India strength) |
| Bear #3: 2026 deceleration | Disproven (Q1 +16%) |
| Bear #4: ACA/Medicaid policy | Watch List |
| Bear #5: Cyber incident | Contained |
Action: Maintaining Outperform with HIGH conviction. The print is the cleanest validation of multi-quarter compounder thesis. Multiple TAM unlocks visible across 2026-2027.